scholarly journals Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass

2003 ◽  
Vol 50 (6) ◽  
pp. 599-602 ◽  
Author(s):  
Viren N. Naik ◽  
C. David Mazer ◽  
David A. Latter ◽  
Jerome M. Teitel ◽  
Gregory M. T. Hare
Keyword(s):  
Cardiopulmonary Bypass ◽  
Successful Treatment ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Severe Bleeding ◽  
Post Cardiopulmonary Bypass

Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation

2004 ◽  
Vol 30 (6) ◽  
pp. 1232-1234 ◽  
Author(s):  
S. E. M. J. Gielen-Wijffels ◽  
W. N. K. A. van Mook ◽  
S. van der Geest ◽  
G. Ramsay
Keyword(s):  
Kidney Transplantation ◽  
Successful Treatment ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Severe Bleeding

scholarly journals Successful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient

2006 ◽  
Vol 105 (9) ◽  
pp. 765-769 ◽  
Author(s):  
Yu-Feng Wei ◽  
Chao-Chi Ho ◽  
Ming-Tzer Lin ◽  
Ang Yuan ◽  
Chong-Jen Yu
Keyword(s):  
Successful Treatment ◽  
Recombinant Factor Viia ◽  
Factor Viia

Recombinant Factor VIIa

2007 ◽  
Vol 18 (2) ◽  
pp. 141-148
Author(s):  
Louise Rose
Keyword(s):  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Case Reports ◽  
Controlled Trial ◽  
Red Blood Cell Transfusion ◽  
Severe Bleeding ◽  
Trauma Patients ◽  
Safety Issues ◽  
Uncontrolled Bleeding

Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest. rFVIIa was initially developed (and licensed) for the treatment of hemophilia. Increasingly, evidence suggests rFVIIa causes cessation of bleeding, improves coagulation markers, and reduces blood product use for treatment of severe bleeding due to other causes. The majority of evidence for nonlicensed use of rFVIIa consists of case reports. Recently, the first randomized controlled trial of rFVIIa in trauma patients reported a significant reduction in red blood cell transfusion, and a trend toward reduced mortality and critical complications. As evidence builds to support the use of rFVIIa, nurses need to be aware of the administration and safety issues of this treatment.

Successful Treatment of Severe Gastrointestinal Bleeding Secondary to Crohn Disease with Recombinant Factor VIIa

2007 ◽  
Vol 100 (6) ◽  
pp. 601-604 ◽  
Author(s):  
Eva Girona ◽  
Joaquín Borrás-Blasco ◽  
Venancio Conesa-García ◽  
Andrés Navarro-Ruiz ◽  
Javier Solís ◽  
...  
Keyword(s):  
Gastrointestinal Bleeding ◽  
Successful Treatment ◽  
Crohn Disease ◽  
Recombinant Factor Viia ◽  
Factor Viia
Sign in / Sign up

Export Citation Format

Share Document